(Q38127715)

29 August 2017

0 references

DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis (English)

1 reference

29 August 2017

1 reference

1 reference

4

Romano Danesi

1 reference

29 August 2017

Salvatore Terrazzino

1

1 reference

29 August 2017

Sarah Cargnin

2

1 reference

29 August 2017

Marzia Del Re

3

1 reference

29 August 2017

Pier Luigi Canonico

5

1 reference

29 August 2017

Armando A Genazzani

6

1 reference

29 August 2017

publication date

1 August 2013

1 reference

29 August 2017

1 reference

29 August 2017

volume

14

1 reference

29 August 2017

issue

11

1 reference

29 August 2017

page(s)

1255-1272

1 reference

29 August 2017

cites work

Capecitabine: a review

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.116

A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.116

Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.116

Screening for dihydropyrimidine dehydrogenase deficiency: to do or not to do, that's the question

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.116

Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.116

A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.116

Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.116

5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.116

Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.116

Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.116

Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.116

Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.116

High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.116

Mutations in exon 14 of dihydropyrimidine dehydrogenase and 5-Fluorouracil toxicity in Portuguese colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.116

A comparative analysis of translated dihydropyrimidine dehydrogenase cDNA; conservation of functional domains and relevance to genetic polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.116

Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.116

STrengthening the REporting of Genetic Association Studies (STREGA): An Extension of the STROBE Statement

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.116

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.116

Synthesis of genetic association studies for pertinent gene-disease associations requires appropriate methodological and statistical approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.116

Quantitative synthesis in systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.116

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.116

A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.116

Operating characteristics of a rank correlation test for publication bias

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.116

Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemothera

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.116

Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.116

Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.116

Phase II study of preoperative radiation plus concurrent daily tegafur-uracil (UFT) with leucovorin for locally advanced rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.116

Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean population for prediction of 5-fluorouracil-associated toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.116

Meta-analysis of rare and adverse event data

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.116

Pharmacogenetics: from bench to byte--an update of guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.116

Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.116

Novel disease-causing mutations in the dihydropyrimidine dehydrogenase gene interpreted by analysis of the three-dimensional protein structure

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.116

The contribution of deleterious DPYD gene sequence variants to fluoropyrimidine toxicity in British cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.116

Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.116

Promoter methylation and large intragenic rearrangements of DPYD are not implicated in severe toxicity to 5-fluorouracil-based chemotherapy in gastrointestinal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.116

Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.116

Lack of large intragenic rearrangements in dihydropyrimidine dehydrogenase (DPYD) gene in fluoropyrimidine-treated patients with high-grade toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.116

Absence of large intragenic rearrangements in the DPYD gene in a large cohort of colorectal cancer patients treated with 5-FU-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.116

Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.116

Pharmacokinetics of orally administered uracil in healthy volunteers and in DPD-deficient patients, a possible tool for screening of DPD deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.116

Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.116

Functional polymorphisms of folate metabolism and response to chemotherapy for colorectal cancer, a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.13.116

21 January 2018

Identifiers

DOI

10.2217/PGS.13.116

1 reference

29 August 2017

1 reference